Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries is currently trading at Rs. 836.40, down by 110.40 points or 11.66% from its previous closing of Rs. 946.80 on the BSE.

The scrip opened at Rs. 852.15 and has touched a high and low of Rs. 852.15 and Rs. 799.05 respectively. So far 1501227 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1200.70 on 07-Apr-2015 and a 52 week low of Rs. 741.90 on 24-Jul-2014.

Last one week high and low of the scrip stood at Rs. 957.00 and Rs. 799.05 respectively. The current market cap of the company is Rs. 203751.86 crore.

The promoters holding in the company stood at 63.56% while Institutions and Non-Institutions held 24.52% and 11.91% respectively.

Sun Pharmaceutical Industries has decided to discontinue certain non-strategic businesses of Ranbaxy Laboratories. This move is a part of the integration process. The company expects to incur certain integration charges in order to generate long-term synergies from this merger. The company has embarked on various consolidation initiatives globally to drive future growth and profitability and to enhance long-term shareholder value.

The company also continues to allocate significant resources to R&D in order to strengthen the specialty pipeline including patented products and complex generics. This will mandate increased R&D investments including that for the development of MK-3222.

Sun Pharmaceutical Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.